SLC12A2 and gastric adenocarcinoma: Preclinical studies have recently shown that inhibition of the NKCC1 could slow cancer cell deterioration by influencing cancer cell growth and metastasis [11], and furosemide could reduce cell growth in poorly differentiated gastric adenocarcinoma cells [12].